Cover Image

Does size matter?: Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy : acute myeloid leukemia

We investigated the effect of center-specific variables on overall survival (OS) after allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML). Eligible for the study were adult patients reported to the German Registry for Hematopoietic Stem Cell Transplantation and C...

Full description

Saved in:
Bibliographic Details
Main Authors: Bethge, Wolfgang Andreas (Author) , Flossdorf, Sarah (Author) , Hanke, Franziska (Author) , Schmid, Christoph (Author) , Ringhoffer, Mark (Author) , Klein, Stefan (Author) , Hertenstein, Bernd (Author) , Schetelig, Johannes (Author) , Stelljes, Matthias (Author) , Schroeder, Thomas (Author) , Blau, Igor Wolfgang (Author) , Ayuk, Francis (Author) , Eder, Matthias (Author) , Zeiser, Robert (Author) , Fleischhauer, Katharina (Author) , Kröger, Nicolaus (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: June 2025
In: Haematologica
Year: 2025, Volume: 110, Issue: 6, Pages: 1292-1303
ISSN:1592-8721
DOI:10.3324/haematol.2024.286385
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3324/haematol.2024.286385
Verlag, kostenfrei, Volltext: https://haematologica.org/article/view/11863
Get full text
Author Notes:Wolfgang Bethge, Sarah Flossdorf, Franziska Hanke, Christoph Schmid, Mark Ringhoffer, Stefan Klein, Bernd Hertenstein, Johannes Schetelig, Matthias Stelljes, Thomas Schroeder, Igor Wolfgang Blau, Francis Ayuk, Matthias Eder, Robert Zeiser, Katharina Fleischhauer, Nicolaus Kröger and Peter Dreger; on behalf of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT)and the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
Description
Summary:We investigated the effect of center-specific variables on overall survival (OS) after allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML). Eligible for the study were adult patients reported to the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST) receiving first alloHCT for AML from a related or matched (>9/10 HLA-match) unrelated donor in the period 2015-2021. Primary endpoint was OS at 12 months from alloHCT. Univariable and multivariable analyses after best subset selection were performed. Of 5,328 patients, 83% received alloHCT in a high-volume center (≥40 alloHCT/year), 90% in a university hospital, 90% in a center performing alloHCT for ≥10 years, and 73% in a Joint Accreditation Committee ISCT-Europe & European Group for Blood and Marrow Transplantation (EBMT) (JACIE) accredited center. 52% of the patients were in first CR, and European LeukemiaNet risk was adverse in 37% and intermediate in 42%. On multivariable analysis, center-specific factors predicting adverse 12-month OS were program duration <5-10 years (Hazard Ratio [HR] 1.23, [95% Confidence Interval: [1.02; 1.49]), center volume <40 alloHCT/year (HR 1.21, [1.02; 1.45]), and treatment at a non-university hospital (HR 1.21, [0.98; 1.49]), whereas JACIE accreditation did not. Spline modeling suggested a negative effect of a center volume up to 45 alloHCT per year. Center volume, center experience, university hospital, but not JACIE accreditation, have an impact on alloHCT outcomes in adult patients with AML in Germany.
Item Description:Gesehen am 25.09.2025
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2024.286385

Similar Items